Research Topics
| Christopher J HoffmannSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
|
Detail Information
Publications
Hepatitis B and long-term HIV outcomes in coinfected HAART recipientsChristopher J Hoffmann
Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA
AIDS 23:1881-9. 2009..Chronic hepatitis B (CH-B) is common among HIV-infected individuals and increases liver-related mortality in the absence of HAART. The impact of CH-B on long-term HAART outcomes has not been fully characterized...- Clinical implications of HIV and hepatitis B co-infection in Asia and AfricaChristopher J Hoffmann
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Lancet Infect Dis 7:402-9. 2007..This Review discusses the epidemiology, natural history, pathogenesis, and management of HIV/HBV co-infection from these areas. Topics for future research relevant to HIV/HBV co-infection in Africa and Asia are also highlighted... - Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis BChristopher J Hoffmann
Aurum Institute for Health Research, Johannesburg, South Africa
AIDS 21:1301-8. 2007..Hepatotoxicity is a significant complication of antiretroviral therapy (ART). We assessed the incidence of and risk factors for hepatotoxicity among HIV-infected individuals on ART in South Africa... - Changing predictors of mortality over time from cART start: implications for careChristopher J Hoffmann
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Acquir Immune Defic Syndr 58:269-76. 2011..To determine predictors of mortality and changes in those predictors over time on combination antiretroviral therapy (cART) in South Africa... - Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical eventsChristopher J Hoffmann
Aurum Institute for Health Research, Johannesburg, South Africa
AIDS 22:67-74. 2008..To describe the safety and tolerability of zidovudine, lamivudine, and efavirenz in a low-income setting... - Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South AfricaChristopher J Hoffmann
Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA
Clin Infect Dis 49:1928-35. 2009..Episodes of viremia are common in African antiretroviral therapy (ART) programs. We sought to describe viremia, resuppression, and accumulation of resistance during first-line combination ART (cART) in South Africa... - Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South AfricaChristopher J Hoffmann
Aurum Institute, Johannesburg, South Africa
AIDS 24:1709-16. 2010..To assess the effectiveness of cotrimoxazole preventive therapy (CPT) among individuals with CD4 cell count above 200 cells/microl and varying WHO clinical stages in reducing mortality during combination antiretroviral therapy (cART)... - Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART programChristopher J Hoffmann
Aurum Institute for Health Research and 2Toga Laboratories, Johannesburg, South Africa
Clin Infect Dis 47:1479-85. 2008..We evaluated the impact of chronic hepatitis B on HIV virologic response, changes in CD4 cell count, hepatotoxicity, and mortality among Africans receiving highly active antiretroviral therapy (HAART)... - Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programmeSalome Charalambous
The Aurum Institute, Johannesburg, South Africa
AIDS 24:S5-13. 2010..To describe the association between isoniazid preventive therapy (IPT) and mortality among individuals starting antiretroviral therapy (ART) in a workplace programme in South Africa where tuberculosis (TB) incidence is very high... - HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South AfricaChristopher J Hoffmann
Aurum Institute for Health Research, Johannesburg, South Africa
AIDS 23:1784-6. 2009..6). In regression modeling, including baseline HIV RNA and nonnucleoside reverse transcriptase inhibitor agent, stavudine dose remained unassociated with suppression... - A novel HIV treatment model using private practitioners in South AfricaCraig Innes
The Aurum Institute, Johannesburg, South Africa
Sex Transm Infect 88:136-40. 2012..The extent of the HIV epidemic in South Africa may render the public sector capacity inadequate to manage all patients requiring antiretroviral treatment (ART). Private practitioners are an underutilised resource... - Epidemiology of tuberculosis and HIV: recent advances in understanding and responsesNeil A Martinson
Center for TB Research, Johns Hopkins University School of Medicine, Baltimore Maryland 21231, USA
Proc Am Thorac Soc 8:288-93. 2011..Combating TB in high HIV-prevalence settings requires rapid and massive implementation of the 3I's with initiation of antiretrovirals and more effective efforts to prevent new HIV infections... - Initial regimens for the treatment-naive patient: current understanding and practiceChristopher J Hoffmann
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
AIDS Read 18:326-30, 336-8. 2008 - Incidence and risk factors for hepatocellular carcinoma after solid organ transplantationChristopher J Hoffmann
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Transplantation 86:784-90. 2008..Solid organ transplant recipients commonly are infected with hepatitis viruses, are immunosuppressed, and have other potential hepatocellular carcinoma (HCC) risk factors... - Thyroid function abnormalities in HIV-infected patientsChristopher J Hoffmann
Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
Clin Infect Dis 45:488-94. 2007.... - Neurocysticercosis in Oregon, 1995-2000John M Townes
Division of Infectious Diseases, Oregon Health and Science University, Mail Code L 457, 3181 SW Sam Jackson Park Road, Portland, OR 97201 3098, USA
Emerg Infect Dis 10:508-10. 2004..At least five cases occurred in persons who had not traveled or lived outside the United States. Enhanced surveillance for neurocysticercosis is warranted...
Research Grants
- Hepatoxicity in an African HIV Treatment CohortChristopher Hoffmann; Fiscal Year: 2006..It will be conducted within a large and on-going ARV cohort established as a collaborative project between a South African industrial conglomerate and Johns Hopkins University. ..